We read the article by Burkholder et al with interest.1 The study describes a potentially new biomarker, macular volume, in addition to retinal nerve fiber layer thickness to follow up patients with multiple sclerosis (MS) using optical coherence tomography (OCT).2 We offer a few comments regarding their conclusions.